Literature DB >> 9065946

Quality of life in patients with cystic fibrosis.

W de Jong1, A A Kaptein, C P van der Schans, G P Mannes, W M van Aalderen, R G Grevink, G H Koëter.   

Abstract

The majority of patients with cystic fibrosis (CF) will grow into adulthood. Despite this improvement in survival, the disease is progressive, especially with respect to the decline in pulmonary function, which in turn may have an impact on a patient's quality of life. In this study we evaluated the quality of life in CF adults and examined the relationship between quality of life and pulmonary function, exercise capacity, and dyspnea. We assessed in 15 patients in stable clinical condition their forced expired volume in the first second (FEV1) inspiratory vital capacity (IVC), cycle exercise capacity (Wmax), and subjective degrees of dyspnea during daily living (MRC dyspnea scale). Quality of life was assessed with the Sickness Impact Profile (SIP). A sample of 100 healthy individuals, ranging in age from 18 to 30 years, served as the control group. Mean (SD) age of the patients was 25.9 (7.3) years, FEV1 was 38 (16)% predicted, IVC was 65 (17)% predicted, FEV1 IVC ratio was 46 (10)%, and Wmax was 90 (54) W. The overall SIP and physical SIP scores in CF patients were significantly higher than in the controls, indicating more impairment in overall and physical functioning in the patients than in the control group (P < 0.001). The psychosocial SIP score did not differ significantly between the two groups. Overall SIP score correlated poorly with FEV1 % predicted (r = -0.33; n.s) and IVC % predicted (r = -0.36; n.s.) but showed a better and significant relationship to the maximal exercise capacity (r = -0.57; P < 0.05). MRC dyspnea scores showed a strong correlation with overall SIP scores (r = 0.75; P < 0.001). These results show that CF affects quality of life in adults primarily due to a limitation in physical functioning. Psychosocial functioning did not differ from that of healthy controls. Exercise capacity and dyspnea scores were related to the impairment in the quality of life. Therefore, the effects of programs aimed to improve exercise capacity and reduce dyspnea on CF patients' quality of life need to be evaluated.

Entities:  

Mesh:

Year:  1997        PMID: 9065946     DOI: 10.1002/(sici)1099-0496(199702)23:2<95::aid-ppul4>3.0.co;2-n

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  17 in total

1.  The adaptations of a quality of life questionnaire for routine use in clinical practice: the Chronic Respiratory Disease Questionnaire in cystic fibrosis.

Authors:  J Bradley; M Dempster; E Wallace; S Elborn
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

Review 2.  Physiotherapy in cystic fibrosis.

Authors:  S A Prasad; E L Tannenbaum; C Mikelsons
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

3.  Comparison of three generic questionnaires measuring quality of life in adolescents and adults with cystic fibrosis: the 36-item short form health survey, the quality of life profile for chronic diseases, and the questions on life satisfaction.

Authors:  L Goldbeck; T G Schmitz
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

4.  A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review.

Authors:  Lisa Van Wilder; Elke Rammant; Els Clays; Brecht Devleesschauwer; Nele Pauwels; Delphine De Smedt
Journal:  Qual Life Res       Date:  2019-09-17       Impact factor: 4.147

5.  Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients.

Authors:  Bernadette Henry; Pierre Aussage; Cécile Grosskopf; Jean-Marie Goehrs
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

Review 6.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 7.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Management issues for adolescents with cystic fibrosis.

Authors:  Adelaide Lindsay Withers
Journal:  Pulm Med       Date:  2012-09-06

9.  The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study.

Authors:  Katerina Manika; Georgia G Pitsiou; Afroditi K Boutou; Vassilis Tsaoussis; Nikolaos Chavouzis; Marina Antoniou; Maria Fotoulaki; Ioannis Stanopoulos; Ioannis Kioumis
Journal:  Pulm Med       Date:  2012-07-29

Review 10.  Global Burden of Anxiety and Depression among Cystic Fibrosis Patient: Systematic Review and Meta-Analysis.

Authors:  Mistire Teshome Guta; Tiwabwork Tekalign; Nefsu Awoke; Robera Olana Fite; Getahun Dendir; Tsegaye Lolaso Lenjebo
Journal:  Int J Chronic Dis       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.